The Common Variant rs11646213 Is Associated with Preeclampsia in Han Chinese Women

Ji-peng Wan1, Han Zhao2,3,4,5, Tao Li2,3,4,5, Chang-zhong Li1, Xie-tong Wang1*, Zi-Jiang Chen2,3,4,5,6,7

1 Department of Obstetrics and Gynecology, Provincial Hospital Affiliated to Shandong University, Jinan, China, 2 Center for Reproductive Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, China, 3 National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Jinan, China, 4 The Key Laboratory for Reproductive Endocrinology of Ministry of Education, Jinan, China, 5 Shandong Provincial Key Laboratory of Reproductive Medicine, Jinan, China, 6 Center for Reproductive Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 7 Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China

Abstract

Background: Preeclampsia, characterized by hypertension and proteinuria, is a multifactorial disease caused by complex interactions between environmental and genetic factors. A recent genome-wide association study of blood pressure reported an association between hypertension and rs11646213. This study evaluated the association between preeclampsia and rs11646213.

Methods: A total of 454 cases and 460 controls were recruited to participate in this study. The single nucleotide polymorphism (SNP) rs11646213 was genotyped by polymerase chain reaction (PCR) and direct sequencing.

Results: The allele frequency of rs11646213 was significantly different between the preeclampsia and control groups (P = 0.017, OR = 1.36, 95% CI = 1.06–1.76). Differences were particularly significant in the severe preeclampsia subgroup (P = 0.002, OR = 1.54, 95% CI = 1.17–2.03) and the early-onset preeclampsia subgroup (P = 0.004, OR = 1.57, 95% CI = 1.16–2.13). Genotyping analysis showed that the T allele of rs11646213 could confer a risk for preeclampsia, severe preeclampsia and early-onset preeclampsia.

Conclusions: Rs11646213 upstream of the CDH13 gene is associated with preeclampsia in Han Chinese women.

Introduction

Preeclampsia affects approximately 2.5% to 3% of all pregnancies and is a leading cause of maternal morbidity and mortality in developing countries [1]. Although the exact pathogenesis of preeclampsia remains unclear, proposed mechanisms include endothelial cell dysfunction, intravascular inflammation, oxidative stress and angiogenesis imbalance [2–4]. Data has shown that daughters and sisters of women with preeclampsia are prone to developing preeclampsia, indicating that genetic factors play a significant role in the pathogenesis [5]. Twin studies estimated the heritability of preeclampsia to be approximately 22%–54% [6,7].

Epidemiological studies have shown that women with chronic hypertension are at an increased risk of developing preeclampsia and that a family history of chronic hypertension is more common in preeclamptic patients compared with controls [8–11]. A genome-wide association study (GWAS) of blood pressure has reported that the single nucleotide polymorphism (SNP) rs11646213 located upstream of the cadherin 13 preprotein (CDH13) gene is associated with hypertension in Europeans [12]. Another European study confirmed that the T allele of the SNP rs11646213 conferred a risk for developing hypertension [13].

Thus, we proposed that SNP rs11646213 might be a genetic risk factor for preeclampsia and investigated the association between preeclampsia and rs11646213 in a cohort of Han Chinese women.

Materials and Methods

Ethics Statement

The study was approved by the Institutional Review Board of the Provincial Hospital Affiliated to Shandong University. And written informed consent was obtained from each participant.

Subjects

A total of 914 Han Chinese pregnant women who visited Provincial Hospital Affiliated to Shandong University were enrolled from December 2009 to November 2011. Controls were normotensive women with no antenatal medical or obstetric complications, presenting normal fetal growth at ≥37 weeks of gestation (birth weight between the 10th and the 90th percentile), and with a regular postpartum course. Preeclampsia was defined as gestational hypertension with proteinuria (the presence of blood pressure values ≥140/90 mm Hg on 2 measurements at least 6 hours apart; 24 hour urinary protein ≥300 mg or urine dipstick

Citation: Wan J-p, Zhao H, Li T, Li C-z, Wang X-t, et al. (2013) The Common Variant rs11646213 Is Associated with Preeclampsia in Han Chinese Women. PLoS ONE 8(8): e71202. doi:10.1371/journal.pone.0071202

Editor: Hai-Yan Lin, Chinese Academy of Sciences, China

Received May 22, 2013; Accepted July 3, 2013; Published August 19, 2013

Copyright: © 2013 Wan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by National Basic Research Program of China (973 Program) (2011CB944502) and the National Natural Science Foundation of China (81170590). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: wangxiet@gmail.com
protein ≥ 5) after the 20th week of pregnancy in a previously normotensive and non-proteinuric woman [14]. Blood pressure and proteinuria cut-offs for classifying the cases as mild preeclampsia or severe preeclampsia were greater than 160/110 mmHg and 24 hour urinary protein ≥ 5 g or urine dipstick protein ≥ 3+, respectively [14]. Early-onset preeclampsia was defined as manifestation before 34 gestational weeks and late-onset preeclampsia thereafter.

Blood pressure was measured in the right arm after a 5-minute period of rest. The following clinical data were collected: maternal age, parity, gestational age at birth, fetal weight and prepregnancy body mass index (pre-BMI). Participants were excluded for the following reasons: a previous renal, autoimmune, metabolic or cardiovascular disease, chronic hypertension, lost to follow-up and multiple pregnancies. Women with gestational hypertension, preeclampsia and controls (P = 0.27, OR = 1.19, 95% CI = 0.87–1.62), although no difference was found between late-onset preeclampsia and the controls (P = 0.004, OR = 1.57, 95% CI = 1.16–2.03), but not mild preeclampsia (P = 0.91, OR = 1.02, 95% CI = 0.70–1.50). The MAF was also significantly different between early-onset preeclampsia and the controls (P = 0.004, OR = 1.57, 95% CI = 1.16–2.13), although no difference was found between late-onset preeclampsia and controls (P = 0.27, OR = 1.19, 95% CI = 0.87–1.62).

Women with preeclampsia were further divided into four subgroups: early-onset mild preeclampsia (28 cases), early-onset severe preeclampsia (183 cases), late-onset mild preeclampsia (121 cases) and late-onset severe preeclampsia (122 cases). The MAF

### Statistical analysis

General characteristics of the cases and controls were expressed as mean ± SD. Linkage disequilibrium (LD) was assessed using Haploview software (Broad Institute, Cambridge, MA, USA). The chi-square test was performed to compare allele frequency. Genetic models were divided into additive (+/+ vs. +/− vs. −/−), dominant (+/+) plus (+/− vs. −/−) and recessive (+/+) vs. (+/− plus (−/−) groups and analyzed by one-way ANOVA. Unconditional logistic regression analysis was used for parity, pre-BMI and maternal age adjustments using SPSS statistical software (version 17.0; SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.

Table 1. Clinical characteristics of women with and without preeclampsia.

| Characteristics | Control (N = 460) | PE (N = 454) | PE Early-onset (N = 211) | PE Late-onset (N = 243) |
|-----------------|-----------------|-------------|------------------------|------------------------|
| Maternal age    | 28.1 ± 5.0      | 29.0 ± 5.5a | 28.6 ± 5.3             | 29.2 ± 5.6b            |
| Pre-BMI         | 22.1 ± 3.2      | 24.2 ± 3.9a | 23.4 ± 3.5b            | 24.5 ± 3.9b            |
| Primiparas      | 264 (57.4%)     | 280 (61.7%) | 261 (61.1%)            | 282 (61.9%)            |
| SBP (mmHg)      | 118.6 ± 10.0    | 163.1 ± 20.1a| 148.4 ± 15.1a          | 170.2 ± 18.3b          |
| DBP (mmHg)      | 76.3 ± 7.1      | 107.2 ± 14.2a| 99.6 ± 12.1a           | 114.8 ± 13.4b          |
| Delivery weeks  | 39.2 ± 13.3     | 35.9 ± 3.5a | 36.8 ± 2.9             | 35.1 ± 3.7b            |
| Fetal weight(g) | 3398.5 ± 482.8  | 2539.7 ± 926.9| 2818.1 ± 970.1a        | 2371.2 ± 875.1b        |

Notes: PE = preeclampsia; MPE = mild preeclampsia; SPE = severe preeclampsia; Pre-BMI = prepregnancy body mass index; SBP = Blood pressure, systolic; DBP = Blood pressure, diastolic.

### Results

The clinical characteristics of the cases and controls are shown in Table 1. Women with preeclampsia had a higher pre-BMI and mean maternal age than the controls (P < 0.05). Gestational age at birth and fetal weight were significantly lower among cases compared with controls (P < 0.05).

No deviation of allele frequencies from Hardy–Weinberg equilibrium was found in both the cases and controls. As shown in Table 2, the minor allele frequency (MAF) was significantly different between the case and control groups (PE vs. control: OR = 1.36, 95% CI = 1.06–1.76). Relative to the controls, an association with rs11646213 was observed in women with severe PE (OR = 1.54, 95% CI = 1.17–2.03), but not mild preeclampsia (OR = 1.02, 95% CI = 0.70–1.50). The MAF was also significantly different between early-onset preeclampsia and the controls (OR = 1.57, 95% CI = 1.16–2.13), although no difference was found between late-onset preeclampsia and controls (OR = 1.19, 95% CI = 0.87–1.62).

Women with preeclampsia were further divided into four subgroups: early-onset mild preeclampsia (28 cases), early-onset severe preeclampsia (183 cases), late-onset mild preeclampsia (121 cases) and late-onset severe preeclampsia (122 cases). The MAF

Table 2. Allele frequencies of rs11646213 in women with and without preeclampsia.

| Allele (T/A) | MAF | P | OR(95% CI) | P adjust * |
|-------------|-----|---|------------|------------|
| Control     | 124/796 | 0.135 | 0.017 | 1.36(1.06–1.76) | 0.046 |
| PE          | 159/749 | 0.175 | 0.001 | 1.54(1.17–2.03) | 0.054 |
| PE M PE     | 41/257  | 0.138 | 0.091 | 1.02(0.70–1.50) | 0.352 |
| S PE        | 118/492 | 0.193 | 0.002 | 1.57(1.16–2.13) | 0.040 |
| PE Early-onset | 83/339  | 0.197 | 0.004 | 1.57(1.16–2.13) | 0.040 |
| Late-onset  | 76/410  | 0.156 | 0.271 | 1.90(0.87–4.22) | 0.330 |

Notes: PE = preeclampsia; MAF = minor allele frequency; OR = odds ratio between case and control group; 95% CI = 95% confidence interval.

*The P value was adjusted by parity, pre-BMI and maternal age.

doi:10.1371/journal.pone.0071202.t0002
was significantly different between early-onset severe preeclampsia and controls ($P = 0.003$). No significant differences were observed between the controls and other subgroups (Table S1).

Genotype frequency was further analyzed under additive, recessive and dominant models (Table 3). Significant differences were identified between cases and controls under the additive ($P = 0.006$) and dominant models ($P = 0.010$). There was a significant difference between severe preeclampsia and the controls under additive ($P = 0.006$) and dominant models ($P = 0.001$). Similar results were observed in the early-onset group under additive ($P = 0.013$) and dominant models ($P = 0.019$).

### Discussion

In the present study, a significant association between preeclampsia and rs11646213 was identified in a cohort of Han Chinese women. When the cases were divided into subgroups, there was a significant association between early-onset severe preeclampsia and the controls.

The participants were all Han Chinese women in our study, so that there was no variation in genetic background. The T allele, which confers an increased risk of developing preeclampsia, was the minor allele. As shown in the GWAS blood pressure study, the T allele is the risk allele.

In conclusion, we identified a significant association between rs11646213 and preeclampsia in Han Chinese women.

### Supporting Information

#### Table S1 Allele frequencies of rs11646213 in control, early-onset mild preeclampsia, early-onset severe preeclampsia, late-onset mild preeclampsia and late-onset severe preeclampsia subjects. PE: preeclampsia; MAF: minor allele frequency; OR: odds ratio; 95% CI: 95% confidence interval.

#### Acknowledgments

We are grateful to Peng Wang, Lei Cheng and Guangyu Li of Provincial Hospital Affiliated to Shandong University for sample collecting and technical support. We especially thank all the subjects for participating in this study.

#### Author Contributions

Conceived and designed the experiments: XW CL. Performed the experiments: JW. Analyzed the data: HZ TL. Contributed reagents/materials/analysis tools: ZC. Wrote the paper: ZC JW.

### References

1. Liang J, Zhu J, Dai L, Li X, Li M, et al. (2010) Maternal mortality in China, 1996-2005. International journal of gynecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 110: 93-96.
2. Redman CW, Sargent IL. (2005) Latest advances in understanding preeclampsia. Science 308: 1592-1594.
3. James JL, Whiteley GS, Cartwright JE (2010) Preeclampsia: fitting together the placental, immune and cardiovascular pieces. The Journal of pathology 221: 363-378.
4. Verlohren S, Müller DN, Luft FC, Deckert R (2009) Immunology in Hypertension, Preeclampsia, and Target-Organ Damage. Hypertension 54: 439–443.
5. Morgan T, Ward K (1999) New insights into the genetics of preeclampsia. Seminars in perinatology 23: 14–23.
6. Salonen Ros H, Lichterstein P, Lipworth L, Caanwinus S (2000) Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet 91: 256–260.
7. Thornton JG, Macdonald AM (1999) Twin mothers, pregnancy hypertension and preeclampsia. Br J Obstet Gynaecol 106: 570–573.
8. Odegård RA, Vatten LJ, Nilzen ST, Salvesen KA, Austgulen R (2000) Risk factors and clinical manifestations of pre-eclampsia. BJOG 107: 1410–1416.
9. Duckitt K, Harrington D (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330: 563.
10. Rigo Jr, Rea T, Derzay Z, Derzbach L, Tread A, et al. (2006) Family history of early-onset cardiovascular disorders is associated with a higher risk of severe preeclampsia. European journal of obstetrics, gynecology, and reproductive biology 120: 148–151.
11. Qin C, Williams MA, Lesien WM, Sorensen TK, Frederick IO, et al. (2003) Family history of hypertension and type 2 diabetes in relation to preeclampsia risk. Hypertension 41: 408–413.
12. Org E, Eysteramendy N, Jahanoom P, Giger C, Lichner P, et al. (2009) Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Hum Mol Genet 18: 2288–2296.
13. Fava C, Danese E, Montagnana M, Stigonen M, Almugren P, et al. (2013) A variant upstream of the CDH13 adiponectin receptor gene and metabolic syndrome in Swedes. Am J Cardiol 108: 1432–1437.
14. NHBPEPW Group (2000) Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. American Journal of Obstetrics and Gynecology 183: S1–S22.
15. Ivanov D, Philippova M, Antropova J, Gubaeva F, Iljinskaya O, et al. (2001) Expression of cell adhesion molecule T-cadherin in the human vasculature. Histochemistry and cell biology 115: 231–242.
16. Philippova M, Joshi MB, Pfaff D, Kyriakakis E, Maslova K, et al. (2012) T-cadherin attenuates insulin-dependent signalling, eNOS activation, and angiogenesis in vascular endothelial cells. Cardiovasc Res 93: 498–507.
17. Pfaff D, Philippova M, Kyriakakis E, Maslova K, Rupp K, et al. (2011) Paradoxical effects of T-cadherin on squamous cell carcinoma: up- and down-regulation increase xenograft growth by distinct mechanisms. J Pathol 225: 512–524.
18. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, et al. (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proceedings of the National Academy of Sciences of the United States of America 101: 10308–10313.
19. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, et al. (2010) T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 120: 4342–4352.
20. Wu Y, Li Y, Lange EM, Croteau-Chonka DC, Kuzawa CW, et al. (2010) Genome-wide association study for adiponectin levels in Filipino women identifies CDH13 and a novel uncommon haplotype at KNG1-ADIPOQ. Hum Mol Genet 19: 4935–4946.
21. Chung CM, Liu TH, Chen JW, Lee HB, Yang HC, et al. (2011) A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardio-metabolic outcomes. Diabetes 60: 2417–2423.
22. Morisaki H, Yamanaka I, Iwai N, Miyamoto Y, Kokubo Y, et al. (2012) CDH13 gene coding T-cadherin influences variations in plasma adiponectin levels in the Japanese population. Hum Mutat 33: 402–410.
23. Ling H, Waterworth DM, Stirmadel HA, Pollin TI, Barter PJ, et al. (2009) Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity (Silver Spring) 17: 737–744.
24. Lee SH, Sull JW, Lee JE, Shin C, Park J, et al. (2010) Adiponectin concentrations: a genome-wide association study. Am J Hum Genet 87: 545–552.
25. Ramsay JE, Jamieson N, Greer IA, Sattar N (2003) Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension 42: 891–894.
26. D’Anna R, Bavieria G, Corrado F, Giordano D, Di Benedetto A, et al. (2005) Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. Obstet Gynecol 106: 340–344.
27. D’Anna R, Bavieria G, Corrado F, Giordano D, De Vivo A, et al. (2006) Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG 113: 1264–1269.
28. Masuyama H, Sengawa T, Sumida Y, Masumoto A, Inoue S, et al. (2010) Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG 117: 314–320.
29. Tie W, Yu H, Chen J, Wang X, Chen W, et al. (2009) Expressions of adiponectin receptors in placenta and their correlation with preeclampsia. Reprod Sci 16: 676–684.
30. Junus K, Gentelow M, Wikstrom AK, Larsson I, Hansson SR, et al. (2012) Gene expression profiling of placentae from women with early- and late-onset pre-eclampsia: down-regulation of the angiogenesis-related genes ACVRL1 and EGFL2 in early-onset disease. Mol Hum Reprod 18: 146–155.
31. Oudejans CB, van Dijk M, Oosterkamp M, Lachmeijer A, Blankenstein MA (2007) Genetics of preeclampsia: paradigm shifts. Hum Genet 120: 607–612.